CL2014002986A1 - Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. - Google Patents

Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.

Info

Publication number: CL2014002986A1
Authority: CL; Chile
Prior art keywords: chromen; hydroxy; alkyl; derivatives; optionally substituted
Prior art date: 2012-05-04

Application number

CL2014002986A

Other languages

English (en)

Inventor

Jayaraman Venkat Raman

Swaroop Kumar Venkata Satya Vakkalanka

Original Assignee

Rhizen Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-04

Filing date

2014-11-04

Publication date

2015-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002986(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-04 Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa

2015-01-09 Publication of CL2014002986A1 publication Critical patent/CL2014002986A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
239000012828 PI3K inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CL2014002986A 2012-05-04 2014-11-04 Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. CL2014002986A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN1737CH2012		2012-05-04
US201261671956P	2012-07-16	2012-07-16

Publications (1)

Publication Number	Publication Date
CL2014002986A1 true CL2014002986A1 (es)	2015-01-09

Family

ID=54193684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002986A CL2014002986A1 (es)	2012-05-04	2014-11-04	Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.

Country Status (24)

Country	Link
US (1)	US9309216B2 (es)
EP (1)	EP2844647B1 (es)
JP (2)	JP6290186B2 (es)
KR (1)	KR102073181B1 (es)
CN (2)	CN108084138A (es)
AP (1)	AP3547A (es)
AU (1)	AU2013255469B2 (es)
BR (1)	BR112014027470A2 (es)
CA (1)	CA2871000C (es)
CL (1)	CL2014002986A1 (es)
CO (1)	CO7141413A2 (es)
CY (1)	CY1123456T1 (es)
EA (1)	EA032812B1 (es)
IL (1)	IL235181A (es)
MX (1)	MX365250B (es)
MY (1)	MY171207A (es)
NZ (1)	NZ701198A (es)
PH (1)	PH12014502453B1 (es)
PL (1)	PL2844647T3 (es)
RS (1)	RS61035B1 (es)
SG (1)	SG11201407184PA (es)
SI (1)	SI2844647T1 (es)
WO (1)	WO2013164801A1 (es)
ZA (1)	ZA201407769B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201500895XA (en)	2009-11-05	2015-04-29	Rhizen Pharmaceuticals Sa	Chromen-4-one Derivatives As Kinase Modulators
US9309216B2 (en) *	2012-05-04	2016-04-12	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
US10130635B2 (en)	2012-05-04	2018-11-20	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
EP3004106B1 (en)	2013-06-07	2017-08-30	Rhizen Pharmaceuticals S.A.	Dual selective pi3 delta and gamma kinase inhibitors
EP3160968B1 (en)	2014-06-27	2018-10-31	Rhizen Pharmaceuticals S.A.	Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP2018521044A (ja) *	2015-07-23	2018-08-02	ファーマケア，インク．	リシルオキシダーゼ様２阻害剤とその使用
CN108884049A (zh)	2016-02-09	2018-11-23	法玛克亚公司	喹啉酮赖氨酰氧化酶样2抑制剂及其用途
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
AU2018344739B2 (en) *	2017-10-06	2023-04-13	Shionogi & Co., Ltd.	Stereoselective process for preparing substituted polycyclic pyridone derivatives
WO2023130334A1 (zh) *	2022-01-07	2023-07-13	同润生物医药(上海)有限公司	一种色烯-4-酮化合物及其中间体的制备方法
CN116444521A (zh) *	2022-01-07	2023-07-18	同润生物医药(上海)有限公司	一种色烯-4-酮化合物及其中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62201882A (ja) *	1985-11-18	1987-09-05	Yamanouchi Pharmaceut Co Ltd	イソフラボン誘導体
PE20060426A1 (es) *	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
SG10201500895XA (en) *	2009-11-05	2015-04-29	Rhizen Pharmaceuticals Sa	Chromen-4-one Derivatives As Kinase Modulators
RS58326B1 (sr)	2011-05-04	2019-03-29	Rhizen Pharmaceuticals S A	Nova jedinjenja kao modulatori proteinskih kinaza
US9309216B2 (en) *	2012-05-04	2016-04-12	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CN109970742A (zh) *	2012-07-04	2019-07-05	理森制药股份公司	选择性PI3Kδ抑制剂

2013
- 2013-05-03 US US14/398,902 patent/US9309216B2/en not_active Expired - Fee Related
- 2013-05-03 EP EP13729095.3A patent/EP2844647B1/en active Active
- 2013-05-03 CA CA2871000A patent/CA2871000C/en not_active Expired - Fee Related
- 2013-05-03 RS RS20201267A patent/RS61035B1/sr unknown
- 2013-05-03 AU AU2013255469A patent/AU2013255469B2/en not_active Ceased
- 2013-05-03 CN CN201810028555.5A patent/CN108084138A/zh active Pending
- 2013-05-03 AP AP2014008087A patent/AP3547A/xx active
- 2013-05-03 SG SG11201407184PA patent/SG11201407184PA/en unknown
- 2013-05-03 EA EA201491818A patent/EA032812B1/ru unknown
- 2013-05-03 KR KR1020147034065A patent/KR102073181B1/ko not_active Expired - Fee Related
- 2013-05-03 CN CN201380023361.1A patent/CN104507922B/zh not_active Expired - Fee Related
- 2013-05-03 NZ NZ701198A patent/NZ701198A/en not_active IP Right Cessation
- 2013-05-03 SI SI201331803T patent/SI2844647T1/sl unknown
- 2013-05-03 MX MX2014013426A patent/MX365250B/es active IP Right Grant
- 2013-05-03 PL PL13729095T patent/PL2844647T3/pl unknown
- 2013-05-03 MY MYPI2014003098A patent/MY171207A/en unknown
- 2013-05-03 WO PCT/IB2013/053544 patent/WO2013164801A1/en not_active Ceased
- 2013-05-03 JP JP2015509560A patent/JP6290186B2/ja not_active Expired - Fee Related
- 2013-05-03 BR BR112014027470A patent/BR112014027470A2/pt not_active Application Discontinuation
2014
- 2014-10-19 IL IL235181A patent/IL235181A/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07769A patent/ZA201407769B/en unknown
- 2014-11-03 PH PH12014502453A patent/PH12014502453B1/en unknown
- 2014-11-04 CL CL2014002986A patent/CL2014002986A1/es unknown
- 2014-12-03 CO CO14266920A patent/CO7141413A2/es unknown
2017
- 2017-12-14 JP JP2017239643A patent/JP2018039849A/ja active Pending
2020
- 2020-10-15 CY CY20201100974T patent/CY1123456T1/el unknown

Also Published As

Publication number	Publication date
SG11201407184PA (en)	2014-12-30
US20150087699A1 (en)	2015-03-26
CN108084138A (zh)	2018-05-29
EP2844647A1 (en)	2015-03-11
ZA201407769B (en)	2016-05-25
WO2013164801A1 (en)	2013-11-07
KR102073181B1 (ko)	2020-02-04
PL2844647T3 (pl)	2021-01-25
MX365250B (es)	2019-05-28
AU2013255469A1 (en)	2014-11-13
US9309216B2 (en)	2016-04-12
CO7141413A2 (es)	2014-12-12
CA2871000A1 (en)	2013-11-07
CA2871000C (en)	2021-10-19
JP2018039849A (ja)	2018-03-15
CY1123456T1 (el)	2022-03-24
PH12014502453A1 (en)	2015-03-16
CN104507922B (zh)	2018-02-09
AP3547A (en)	2016-01-14
IL235181A (en)	2017-12-31
NZ701198A (en)	2016-09-30
MX2014013426A (es)	2015-05-11
CN104507922A (zh)	2015-04-08
BR112014027470A2 (pt)	2017-06-27
RS61035B1 (sr)	2020-12-31
JP6290186B2 (ja)	2018-03-07
JP2015515975A (ja)	2015-06-04
EP2844647B1 (en)	2020-07-22
AP2014008087A0 (en)	2014-11-30
HK1203964A1 (en)	2015-11-06
EA032812B1 (ru)	2019-07-31
KR20150006876A (ko)	2015-01-19
EA201491818A1 (ru)	2015-04-30
SI2844647T1 (sl)	2020-12-31
PH12014502453B1 (en)	2019-07-03
MY171207A (en)	2019-10-02
AU2013255469B2 (en)	2017-10-12

Similar Documents

Publication	Publication Date	Title
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
GT201300153A (es)	2014-06-09	Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina
CL2013001604A1 (es)	2014-07-25	Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CO6940429A2 (es)	2014-05-09	Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación
BR112016000489A2 (pt)	2017-07-25	composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
UY35467A (es)	2014-10-31	Compuestos orgánicos
CL2014000732A1 (es)	2014-09-26	Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
SV2018005760A (es)	2019-03-08	Derivados de aminotiazol utiles como agentes antiviricos
MX2015012456A (es)	2016-02-03	Compuestos heterociclicos y usos de los mismos.
MX2015004771A (es)	2016-01-08	Metodos para tratar cancer.
MX2021001231A (es)	2021-04-12	Compuestos heterociclicos y sus usos.
CL2014003566A1 (es)	2015-04-10	Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
CL2014001793A1 (es)	2014-11-07	Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014000183A1 (es)	2014-07-11	Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
BR112015022191A2 (pt)	2017-10-10	compostos heteroarila, seu uso e composição que os compreende
GT201400144A (es)	2015-11-24	Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35210A (es)	2014-07-31	Inhibidores de autotaxina
CR20140275A (es)	2014-08-13	Triazolopiridinas sustituidas
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CO6920294A2 (es)	2014-04-10	Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO7020907A2 (es)	2014-08-11	Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
CL2014001399A1 (es)	2014-11-03	Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion.